DNAprint Genomics (DNAG)

[chiggah]

lizm67,

It is just my opinion and nothing more, but I believe that when our research at Moffitt began quite awhile ago, Gomez already had been in close contact with Merck and that Merck said go ahead and do the research and keep us informed.

With a close eye on results that were obviously productive, Merck began to see thru Gomez, Moffitt and DnaPrint a direction for the future. All of the big Pharms face the same challenges; expiration of patents and generics; multiple lawsuits, and their own little share of over 160,000 people killed every year by reactions to pharmaceuticals, not to mention injuries and higher medical costs,; all of which now show promise of being reduced by using pharmacogenomics.
And now the FDA is taking the progressive road by demanding this kind of resaerch.
Top it off with DNAPrint's supposed ability to stream line drug certification and approval by computational methods saving possibly 100's of millions of dollars and precious time.
This is what I think is going on, and has been for awhile.
Some people say insider info would sneak out and we would see it in the ssp if it were true. I am not so sure of that.
Remember, Gomez already worked with Merck and they all know the importance high level discretion.